LILLY CORPORATE CTR, INDIANAPOLIS, IN
Eli Lilly Completes $750 Million Floating Rate Notes Offering
Shareholder votes
Reports First-Quarter 2026 Financial Results, Raises Full Year Guidance, and Highlights Momentum of New Medicines
Reports Fourth-Quarter 2025 Financial Results and Provides 2026 Guidance
Board Appointment - Carolyn R. Bertozzi Joins Eli Lilly Board
Reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Reports second-quarter 2025 financial results and raises guidance
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus Filed Pursuant to Rule 424(b)(2)
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Soliciting Materials
Definitive Additional Information Statement
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Specialized Disclosure Report
Amended Tender Offer Statement by Third Party
Free Writing Prospectus